METHODS: RCTs were retrieved from various databases (published from inception to February 29, 2024). The effects of the BF and non-BF treatments were compared. A random-effects model was used to evaluate the combined data.
RESULTS: Meta-analysis revealed that BF increased the maximum urinary flow rate (SMD = 3.78, 95% CI 1.33∼6.22), improved urination time (SMD = 5.88, 95% CI 3.75∼8.01), and reduced the postvoid residual (SMD = -19.18, 95% CI -27.03∼-11.33) and urinary tract infection incidence (RR = 0.43, 95% CI 0.21∼0.87). Electromyogram activity (RR = 0.46, 95% CI 0.25∼0.84) and abnormal urination patterns (RR = 0.51, 95% CI 0.35∼0.74) improved, with effects persisting for more than 1 year. However, the effect of BF on the mean urinary flow rate in children with NDV was significant only after 1 year of follow-up (SMD = 1.90, 95% CI 0.87∼2.92).
CONCLUSIONS: Existing evidence indicates that BF can enhance urinary parameters and patterns in children with NDV. However, its effectiveness in addressing constipation, daytime urinary incontinence, and nocturnal urinary incontinence is not substantial. High-quality randomized controlled trials can offer additional insights.
方法:RCT从各种数据库中检索(从开始到2024年2月29日发布)。比较了BF和非BF处理的效果。使用随机效应模型来评估组合数据。
结果:荟萃分析显示BF增加了最大尿流率(SMD=3.78,95%CI1.33~6.22),改善排尿时间(SMD=5.88,95%CI3.75~8.01),并降低了尿路感染后残留(SMD=-19.18,95%CI-27.03~-11.33)和尿路感染发生率(RR=0.43,95%CI0.21~0.87)。肌电图活动(RR=0.46,95%CI0.25~0.84)和排尿异常模式(RR=0.51,95%CI0.35~0.74)改善,效果持续超过1年。然而,仅随访1年后,BF对NDV患儿平均尿流率的影响才有统计学意义(SMD=1.90,95%CI0.87~2.92)。
结论:现有证据表明,BF可以增强NDV患儿的尿路参数和模式。然而,它在解决便秘方面的有效性,白天尿失禁,夜间尿失禁并不严重。高质量的随机对照试验可以提供更多的见解。